ZBED5-AS1: A Potential Drug Target and Biomarker (G729013)

Target Name: ZBED5-AS1

NCBI ID: G729013

ZBED5-AS1

Other Name(s): ZBED5 antisense RNA 1

ZBED5-AS1: A Potential Drug Target and Biomarker

ZBED5-AS1, a gene encoding for a protein known as ZBED5, has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ZBED5 is a non-coding RNA molecule that has been shown to play a critical role in regulating gene expression and cell signaling pathways. In this article, we will explore the biology and potential clinical applications of ZBED5-AS1.

The ZBED5 gene

The ZBED5 gene is located on chromosome 6 and encodes a protein with 214 amino acid residues. The protein has several unique features, including a long N-terminus, a stem-loop structure in the middle of the protein, and a C-terminus with a potential docking site for protein-protein interactions. ZBED5 is primarily expressed in the brain and nervous system, and its expression has been associated with various neurological and psychiatric disorders.

Function and regulation

Several studies have shown that ZBED5 plays a critical role in regulating gene expression and cell signaling pathways. ZBED5 has been shown to interact with various protein partners, including the transcription factor, NF-kappa-B, and the protein, p16INK4a. ZBED5 has also been shown to play a role in the regulation of cellular processes such as cell adhesion, migration, and survival.

In addition, ZBED5 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, ZBED5 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. Similarly, ZBED5 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Potential drug target and biomarker

The potential drug target for ZBED5 is the regulation of its expression and function. By targeting the ZBED5 gene, researchers hope to develop new treatments for various diseases. For example, if ZBED5 is shown to be involved in the regulation of cancer cell growth, researchers may develop new treatments for cancer. Similarly, if ZBED5 is shown to be involved in the regulation of neurodegenerative diseases, researchers may develop new treatments for neurodegenerative diseases.

In addition to its potential clinical applications, ZBED5 has also been shown to be a potential biomarker for various diseases. The expression of ZBED5 has been shown to be associated with the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that ZBED5 may be a useful biomarker for these diseases.

Conclusion

In conclusion, ZBED5-AS1 is a gene encoding for a protein with potential clinical applications as a drug target and biomarker. The regulation of ZBED5 expression and function is a promising area for research, and further studies are needed to fully understand its role in various diseases.

Protein Name: ZBED5 Antisense RNA 1

The "ZBED5-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZBED5-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets